KR102674191B1 - 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물 - Google Patents

뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물 Download PDF

Info

Publication number
KR102674191B1
KR102674191B1 KR1020177018938A KR20177018938A KR102674191B1 KR 102674191 B1 KR102674191 B1 KR 102674191B1 KR 1020177018938 A KR1020177018938 A KR 1020177018938A KR 20177018938 A KR20177018938 A KR 20177018938A KR 102674191 B1 KR102674191 B1 KR 102674191B1
Authority
KR
South Korea
Prior art keywords
tumor
wnt5a
cells
pharmaceutical composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177018938A
Other languages
English (en)
Korean (ko)
Other versions
KR20170098861A (ko
Inventor
안젤로 루이지 베스코비
엘레나 빈다
Original Assignee
하이퍼스템 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하이퍼스템 에스에이 filed Critical 하이퍼스템 에스에이
Publication of KR20170098861A publication Critical patent/KR20170098861A/ko
Application granted granted Critical
Publication of KR102674191B1 publication Critical patent/KR102674191B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177018938A 2014-12-10 2015-12-09 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물 Active KR102674191B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090029P 2014-12-10 2014-12-10
US62/090,029 2014-12-10
PCT/IB2015/002577 WO2016092378A1 (en) 2014-12-10 2015-12-09 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors

Publications (2)

Publication Number Publication Date
KR20170098861A KR20170098861A (ko) 2017-08-30
KR102674191B1 true KR102674191B1 (ko) 2024-06-11

Family

ID=55353245

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018938A Active KR102674191B1 (ko) 2014-12-10 2015-12-09 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물

Country Status (9)

Country Link
US (2) US10688167B2 (enExample)
EP (1) EP3229831B1 (enExample)
JP (1) JP6921755B2 (enExample)
KR (1) KR102674191B1 (enExample)
AU (1) AU2015359043C1 (enExample)
CA (1) CA2970140A1 (enExample)
DK (1) DK3229831T3 (enExample)
ES (1) ES2796973T3 (enExample)
WO (1) WO2016092378A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
CN111417403B (zh) * 2017-10-25 2024-06-04 温特研究公司 Wnt5a肽在减少癌症干细胞中的作用
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
WO2019207512A2 (en) * 2018-04-24 2019-10-31 Universidade Do Minho A novel oncogene biomarker, method and uses thereof
EP3613757A1 (en) * 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides
EP3666789A1 (en) * 2018-12-14 2020-06-17 Wntresearch AB Linear solution phase routes for wnt hexapeptides
CA3137093A1 (en) * 2019-04-16 2020-10-22 Wntresearch Ab Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CN114081954B (zh) * 2021-10-30 2023-02-28 中国人民解放军陆军军医大学第一附属医院 用于胶质母细胞瘤治疗的药物组合物以及预后的诊断试剂
WO2025088835A1 (ja) * 2023-10-25 2025-05-01 国立大学法人大阪大学 ヒト化抗ｃｋａｐ４抗体又はその抗原結合性断片

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019103A1 (en) * 2008-08-13 2010-02-18 Forskarpatent I Syd Ab The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP1226172A1 (en) * 1999-11-05 2002-07-31 Forskarpatent i Syd AB Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
DK2384763T3 (en) * 2005-05-30 2015-07-20 Wntres Ab Peptide ligand for disrupting cancer cell migration
AU2011205409B2 (en) * 2010-01-12 2015-08-20 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
PL2726880T3 (pl) * 2011-07-01 2019-09-30 Wntresearch Ab Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty
US20140171356A1 (en) 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019103A1 (en) * 2008-08-13 2010-02-18 Forskarpatent I Syd Ab The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer

Also Published As

Publication number Publication date
JP2018500390A (ja) 2018-01-11
EP3229831A1 (en) 2017-10-18
US10688167B2 (en) 2020-06-23
WO2016092378A1 (en) 2016-06-16
EP3229831B1 (en) 2020-03-11
US20200345821A1 (en) 2020-11-05
US20170368158A1 (en) 2017-12-28
DK3229831T3 (da) 2020-06-15
KR20170098861A (ko) 2017-08-30
AU2015359043B2 (en) 2021-09-02
ES2796973T3 (es) 2020-11-30
US11357840B2 (en) 2022-06-14
AU2015359043A1 (en) 2017-06-29
HK1245152A1 (en) 2018-08-24
JP6921755B2 (ja) 2021-08-18
CA2970140A1 (en) 2016-06-16
NZ732532A (en) 2024-10-25
AU2015359043C1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
KR102674191B1 (ko) 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물
US7611711B2 (en) VEGFR-3 inhibitor materials and methods
Tu et al. Legumain induces oral cancer pain by biased agonism of protease-activated receptor-2
Chen et al. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells
ES2363765T3 (es) Agonistas de fgfr.
CN107709359A (zh) Ror1‑ror2结合的调节剂
EA023999B1 (ru) Ингибиторы csf-1r для лечения опухолей головного мозга
Nair Epidermal growth factor receptor family and its role in cancer progression
US10010581B2 (en) Syndecan peptides and polypeptides and uses thereof
KR20140142733A (ko) Egfl7 표적화 및/또는 결합 폴리펩타이드, 그리고 신생혈관생성을 저해하는 방법
US20060281670A1 (en) Compositions and methods for modulating angiogenesis
CN105939724B (zh) 用于治疗和预防转移癌的药物组合物和方法
TWI609692B (zh) 新穎ｓｔｉｐ１多肽及其用途
US10080777B2 (en) Syndecan peptides and polypeptides and uses thereof
Sonavane et al. Controlling Wnt signaling specificity and implications for targeting WNTs pharmacologically
HK1245152B (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
US20240166702A1 (en) Compositions and methods for treating breast cancer
Benvenuti et al. Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer
AU2008200559A1 (en) VEGFR-3 Binding peptides and their use for inhibiting angiogenesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601